Announcements
26 June 2024
Current Oncology Receives an Updated Impact Factor of 2.8 and CiteScore of 3.3
We are pleased to share that the Current Oncology (ISSN: 1718-7729) was awarded an increased Impact Factor of 2.8 in the 2023 Journal Citation Reports™ released by Clarivate in June 2024. The Current Oncology ranks upgraded from Q3 to Q2 (157 among 322 titles) in the “Oncology” category.
Additionally, according to data released by Scopus (Elsevier), the Current Oncology received an updated CiteScore™ of 3.3, an increase of 27% compared with the 2022 metric. Current Oncology’s CiteScore ranks Q3 (238 among 404 titles) in the “Oncology” category.
|
2.82023 Impact Factor |
157/322 (Q2)Oncology |
6,836Citations in 2023 |
|
3.32023 CiteScore |
238/404 (Q3)Oncology |
0.792SNIP |
For further statistics, please visit https://www.mdpi.com/journal/curroncol/stats. For more information about MDPI flagship journals' citation metrics, please see here.
At MDPI, our mission is simple yet powerful, and we strive every day to make scientific research freely accessible to everyone, everywhere. With over 3.5 million authors choosing MDPI, we have established ourselves as a key player driving the open access initiative.
Our journals have received over 13 million citations in the Web of Science, making us the most cited open access publisher. With over 800 institutional partners, MDPI continues to demonstrate its dedication to providing reliable and collaborative publishing services.
Current Oncology Editorial Office
